Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway.

Secchiero P, Rimondi E, di Iasio MG, Agnoletto C, Melloni E, Volpi I, Zauli G.

Clin Cancer Res. 2013 Apr 15;19(8):1949-59. doi: 10.1158/1078-0432.CCR-12-3027. Epub 2013 Mar 6.

2.

The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.

di Iasio MG, Zauli G.

Invest New Drugs. 2013 Apr;31(2):458-60. doi: 10.1007/s10637-012-9882-y. Epub 2012 Oct 2.

PMID:
23054209
3.

Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype.

Tisato V, Zauli G, Voltan R, Gianesini S, di Iasio MG, Volpi I, Fiorentini G, Zamboni P, Secchiero P.

PLoS One. 2012;7(6):e39543. doi: 10.1371/journal.pone.0039543. Epub 2012 Jun 21.

4.

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P.

Haematologica. 2012 Nov;97(11):1722-30. doi: 10.3324/haematol.2012.062083. Epub 2012 Jun 11.

5.

SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.

di Iasio MG, Norcio A, Melloni E, Zauli G.

Invest New Drugs. 2012 Dec;30(6):2403-6. doi: 10.1007/s10637-011-9786-2. Epub 2012 Jan 13.

PMID:
22238073
6.

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.

Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, Secchiero P, Zauli G.

Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13.

7.

Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.

Secchiero P, Rimondi E, di Iasio MG, Voltan R, Gonelli A, Zauli G.

J Cell Physiol. 2012 May;227(5):1829-37. doi: 10.1002/jcp.22910.

PMID:
21732354
8.

Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.

Corallini F, Celeghini C, Rimondi E, di Iasio MG, Gonelli A, Secchiero P, Zauli G.

J Cell Physiol. 2011 Sep;226(9):2279-86. doi: 10.1002/jcp.22564.

PMID:
21660951
9.

Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.

di Iasio MG, Addobbati R, Radillo O, Voltan R.

Invest New Drugs. 2012 Aug;30(4):1761-5. doi: 10.1007/s10637-011-9695-4. Epub 2011 May 31. No abstract available.

PMID:
21626114
10.

Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells.

Rimondi E, di Iasio MG, Gonelli A, Celeghini C, Secchiero P, Zauli G.

Invest New Drugs. 2012 Aug;30(4):1731-5. doi: 10.1007/s10637-011-9675-8. Epub 2011 May 4. No abstract available.

PMID:
21541705
11.

miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.

Zauli G, Voltan R, di Iasio MG, Bosco R, Melloni E, Sana ME, Secchiero P.

Clin Cancer Res. 2011 May 1;17(9):2712-24. doi: 10.1158/1078-0432.CCR-10-3244. Epub 2011 Mar 2.

12.

The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.

Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G.

Clin Cancer Res. 2010 Mar 15;16(6):1824-33. doi: 10.1158/1078-0432.CCR-09-3031. Epub 2010 Mar 9.

13.

Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.

Zauli G, Toffoli B, di Iasio MG, Celeghini C, Fabris B, Secchiero P.

Diabetes. 2010 May;59(5):1261-5. doi: 10.2337/db09-1771. Epub 2010 Feb 25.

14.

The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia.

Secchiero P, di Iasio MG, Melloni E, Voltan R, Celeghini C, Tiribelli M, Dal Bo M, Gattei V, Zauli G.

Leukemia. 2010 Feb;24(2):480-3. doi: 10.1038/leu.2009.215. Epub 2009 Oct 22. No abstract available.

PMID:
19847196
15.

Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.

Zauli G, di Iasio MG, Secchiero P, Dal Bo M, Marconi D, Bomben R, Del Poeta G, Gattei V.

Curr Cancer Drug Targets. 2009 Jun;9(4):510-8.

PMID:
19519319
16.

Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin.

Corallini F, Gonelli A, D'Aurizio F, di Iasio MG, Vaccarezza M.

Eur J Histochem. 2009 Jan-Mar;53(1):19-24.

PMID:
19351609
17.

Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients.

di Iasio MG, Secchiero P, Tiribelli M, Zauli G.

Br J Haematol. 2009 May;145(3):424-6; author reply 426-8. doi: 10.1111/j.1365-2141.2009.07589.x. Epub 2009 Feb 4. No abstract available.

PMID:
19210507
18.

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.

Secchiero P, Melloni E, di Iasio MG, Tiribelli M, Rimondi E, Corallini F, Gattei V, Zauli G.

Blood. 2009 Apr 30;113(18):4300-8. doi: 10.1182/blood-2008-11-187708. Epub 2009 Feb 3.

19.

Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.

Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G.

Stem Cells. 2008 Nov;26(11):2955-63. doi: 10.1634/stemcells.2008-0512. Epub 2008 Sep 4.

20.

The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.

Secchiero P, di Iasio MG, Gonelli A, Zauli G.

Curr Pharm Des. 2008;14(21):2100-10. Review.

PMID:
18691119
21.

Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells.

Secchiero P, Corallini F, Rimondi E, Chiaruttini C, di Iasio MG, Rustighi A, Del Sal G, Zauli G.

Blood. 2008 Feb 1;111(3):1287-94. Epub 2007 Nov 13.

22.

Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.

Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G.

Curr Drug Metab. 2007 May;8(4):395-403.

PMID:
17504227
23.

Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70.

Secchiero P, di Iasio MG, Gonelli A, Barbarotto E, Melloni E, Tiribelli M, Chiaruttini C, Zauli G.

J Cell Physiol. 2007 Oct;213(1):229-36.

PMID:
17476690
24.

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A, Cavazzini F, Campioni D, Fanin R, Cuneo A, Zauli G.

Blood. 2006 May 15;107(10):4122-9. Epub 2006 Jan 26.

25.

Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function.

Baroni M, Mazzola G, Kaabache T, Borgel D, Gandrille S, Vigano' D'Angelo S, Marchetti G, di Iasio MG, Pinotti M, D'Angelo A, Bernardi F.

J Thromb Haemost. 2006 Jan;4(1):186-91.

26.

Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.

Secchiero P, Corallini F, Barbarotto E, Melloni E, di Iasio MG, Tiribelli M, Zauli G.

J Cell Physiol. 2006 Apr;207(1):158-64.

PMID:
16270354
27.

TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release.

Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G.

Blood. 2005 May 1;105(9):3413-9. Epub 2005 Jan 11.

28.

Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.

Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, Pedriali M, Matteuzzi M, Maestri I, Nenci I.

Breast Cancer Res Treat. 2001 Mar;66(2):135-42.

PMID:
11437099
29.

Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms.

Calin GA, di Iasio MG, Caprini E, Vorechovsky I, Natali PG, Sozzi G, Croce CM, Barbanti-Brodano G, Russo G, Negrini M.

Oncogene. 2000 Feb 24;19(9):1191-5.

30.

Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region.

di Iasio MG, Calin G, Tibiletti MG, Vorechovsky I, Benediktsson KP, Taramelli R, Barbanti-Brodano G, Negrini M.

Oncogene. 1999 Feb 25;18(8):1635-8.

31.

Risk of venous thromboembolism and stroke associated with oral contraceptives. Role of congenital thrombophilias.

Pini M, Scoditti U, Caliumi F, Manotti C, Quintavalla R, Pattacini C, Poli T, Tagliaferri A, di Iasio MG, Bernardi F.

Recenti Prog Med. 1996 Jul-Aug;87(7-8):331-7.

PMID:
8831253
32.

Mutation pattern in clinically asymptomatic coagulation factor VII deficiency.

Bernardi F, Castaman G, Pinotti M, Ferraresi P, Di Iasio MG, Lunghi B, Rodeghiero F, Marchetti G.

Hum Mutat. 1996;8(2):108-15.

PMID:
8844208
33.

Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain.

Marchetti G, Castaman G, Pinotti M, Lunghi B, Di Iasio MG, Ruggieri M, Rodeghiero F, Bernardi F.

Br J Haematol. 1995 Aug;90(4):910-5.

PMID:
7669671

Supplemental Content

Loading ...
Support Center